Request a quote
Resource library
Shop
Login
Register
View Profile
SCIEX Now Dashboard

GEN-MKT-18-7897-A

Enter search term

Community Home
Discussions & Blogs
Support
Innovation Advisory Panel

Roxana McCloskey

Why electron-activated dissociation (EAD) improves sequence variant analysis in biopharma LC/MS workflows

Apr 29, 2026 | Biopharma, Blogs | 0 comments

Read time: 4 minutes

In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.

As protein therapeutics increase in complexity, so does the challenge of confirming primary structure with confidence. Mass spectrometry‑based peptide mapping remains the foundation of sequence confirmation workflows. However, traditional LC-MS approaches relying on collision‑induced dissociation (CID) alone can fall short when tasked with identifying challenging or low‑abundance variants.

This is where electron-activated dissociation (EAD) provides an additional angle in characterizing these challenging product quality attributes (PQAs).

The challenge with CID‑only workflows

LC-MS workflows centered on CID fragmentation are a standard approach for peptide mapping. While effective for many applications, there are limitations for some of the more challenging post-translational modifications. For sequence variant analysis:

· CID cannot generate signature fragments for unambiguous differentiation of isomeric amino acids such as leucine (Leu) and isoleucine (Ile)

· CID does not provide efficient fragmentation of long peptides that may contain the amino acid substitutions in sequence variants

· CID preferentially cleaves labile post-translation modifications (PTMs), such as glycosylation, leading to the loss of site-specific information about these critical modifications

These challenges are particularly relevant in biopharma, where mass-neutral substitutions may arise during cell culture or manufacturing and must be confidently assigned. When CID cannot provide clear differentiation, sequence ambiguity remains.

How EAD overcomes these limitations

EAD provides a complementaryand additive fragmentation mechanism that preserves critical structural information while generating informative backbone fragments. By using radical‑driven fragmentation, EAD enables a level of sequence insight that is not achievable with CID alone.

Confident differentiation of Leu and Ile

One of the powerful advantages of EAD is its ability to differentiate amino acid isomers, a persistent analytical challenge. EAD generates diagnostic fragments from isomers like aspartic acid (D) vs. isoaspartic acid (isoD) or isoleucine (Leu) vs. isoleucine (Ile), enabling unambiguous identification of these isomeric residues within peptides. This capability removes a major source of uncertainty in sequence variant analysis.¹

Differentiation of Leu and Ile residues using EAD. EAD can lead to secondary fragmentation of the side chains of Leu and Ile residues in the z ions, producing signature w ions (z-29 and z-43) from the neutral loss of C3H7 (43 Da) for Leu and C2H5 (29 Da) for Ile. The detection of these diagnostic fragments enables unambiguous differentiation of Leu vs. Ile.

Improved detection of low‑abundance sequence variants

EAD increases confidence in identifying sequence variants with its signature fragments. The speed and sensitivity of the ZenoTOF 7600+ system and ZenoTOF 8600 system further support confident characterization by improving the detection of sequence variants present at low levels. By providing clear fragment ion evidence, EAD enables reliable assignment of substitutions that might otherwise be missed or misidentified in CID‑only workflows.

EAD spectrum of a low-abundant V→Xle (Xle=Lue or Ile) sequence variant (<0.05%) of the VVSV peptide in NISTmAb. The detection of a z13-29 (w13) ion in this EAD spectrum shows that the Xle residue is an Ile instead of a Leu.

High sequence coverage in routine peptide mapping

EAD integrates seamlessly into data‑dependent acquisition (DDA) peptide mapping workflows, delivering comprehensive sequence coverage in a single injection. This makes advanced sequence variant analysis practical for routine use without adding unnecessary complexity to established methods.

EAD on the ZenoTOF systems: LC-MS for biopharma workflows

EAD is available on the ZenoTOF 7600 system, ZenoTOF 7600+ system and ZenoTOF 8600 system, making it accessible for both routine characterization and advanced biopharma applications, with the ability to run both CID and EAD in a single injection.

· ZenoTOF 7600 system and ZenoTOF 7600+ system

Enable streamlined EAD‑based peptide mapping workflows with high sensitivity and reproducibility, supporting confident differentiation of amino acid isomers and identification of low‑level sequence variants without extensive method optimization.

· ZenoTOF 8600 system

Delivers enhanced MS sensitivity to support routine detection and characterization of trace‑level PQAs, further extending the power of EAD for advanced biotherapeutic characterization.

Why this matters for biopharmaceutical development

Using EAD-enabled LC-MS workflows alongside CID fragmentation provides greater confidence in sequence variant analysis. This confidence supports better decisions throughout the drug development lifecycle. With EAD, scientists can:

· Confirm primary structure with greater certainty

· Detect sequence variants earlier in development

· Better understand process‑related heterogeneity

· Reduce ambiguity in regulatory‑relevant analyses

Learn more about how EAD can enhance LC-MS workflows in biopharma by providing reliable data to inform critical decision points throughout the development pipeline.

Read the technical notes:

1. Differentiation of leucine and isoleucine for enhanced sequence variant analysis using electron activated dissociation

2. A peptide mapping workflow with improved MS sensitivity for enhanced PQA characterization

Watch the webinar:

Boost biotherapeutic quality: Innovative approaches to sequence variant analysis | Kristen Nields and Riley Schaeffer, Johnson & Johnson innovative medicine

How NFD improves impurity detection and peak integration in CE SDS workflows

CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.

What´s new in SCIEX Now – spring release 2026

At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.

The troubleshooting tool LC-MS users have been waiting for

In today’s fast-paced analytical laboratories, uptime is not just important; it is mission-critical. Whether you are running high-throughput bioanalysis, environmental testing, or pharmaceutical workflows, every minute of LC-MS downtime can impact productivity, data quality, and timelines.

That is why we are excited to introduce a smarter and faster way to troubleshoot.

Posted by

Roxana McCloskey

Roxana has over 15 years of experience in sales and marketing roles in the MS community. As Senior Global Marketing Manager for protein therapeutics at SCIEX, she specializes in communicating innovations in MS and CE-based workflows to the biopharma community.

0 Comments

Submit a Comment Cancel reply

You must be logged in to post a comment.

Roxana McCloskey

Why electron-activated dissociation (EAD) improves sequence variant analysis in biopharma LC/MS workflows

Read time: 4 minutes

This is where electron-activated dissociation (EAD) provides an additional angle in characterizing these challenging product quality attributes (PQAs).

The challenge with CID‑only workflows

LC-MS workflows centered on CID fragmentation are a standard approach for peptide mapping. While effective for many applications, there are limitations for some of the more challenging post-translational modifications. For sequence variant analysis:

· CID cannot generate signature fragments for unambiguous differentiation of isomeric amino acids such as leucine (Leu) and isoleucine (Ile)

· CID does not provide efficient fragmentation of long peptides that may contain the amino acid substitutions in sequence variants

· CID preferentially cleaves labile post-translation modifications (PTMs), such as glycosylation, leading to the loss of site-specific information about these critical modifications

These challenges are particularly relevant in biopharma, where mass-neutral substitutions may arise during cell culture or manufacturing and must be confidently assigned. When CID cannot provide clear differentiation, sequence ambiguity remains.

How EAD overcomes these limitations

EAD provides a complementaryand additive fragmentation mechanism that preserves critical structural information while generating informative backbone fragments. By using radical‑driven fragmentation, EAD enables a level of sequence insight that is not achievable with CID alone.

Confident differentiation of Leu and Ile

Improved detection of low‑abundance sequence variants

High sequence coverage in routine peptide mapping

EAD integrates seamlessly into data‑dependent acquisition (DDA) peptide mapping workflows, delivering comprehensive sequence coverage in a single injection. This makes advanced sequence variant analysis practical for routine use without adding unnecessary complexity to established methods.

EAD on the ZenoTOF systems: LC-MS for biopharma workflows

EAD is available on the ZenoTOF 7600 system, ZenoTOF 7600+ system and ZenoTOF 8600 system, making it accessible for both routine characterization and advanced biopharma applications, with the ability to run both CID and EAD in a single injection.

· ZenoTOF 7600 system and ZenoTOF 7600+ system

Enable streamlined EAD‑based peptide mapping workflows with high sensitivity and reproducibility, supporting confident differentiation of amino acid isomers and identification of low‑level sequence variants without extensive method optimization.

· ZenoTOF 8600 system

Delivers enhanced MS sensitivity to support routine detection and characterization of trace‑level PQAs, further extending the power of EAD for advanced biotherapeutic characterization.

Why this matters for biopharmaceutical development

Using EAD-enabled LC-MS workflows alongside CID fragmentation provides greater confidence in sequence variant analysis. This confidence supports better decisions throughout the drug development lifecycle. With EAD, scientists can:

· Confirm primary structure with greater certainty

· Detect sequence variants earlier in development

· Better understand process‑related heterogeneity

· Reduce ambiguity in regulatory‑relevant analyses

Learn more about how EAD can enhance LC-MS workflows in biopharma by providing reliable data to inform critical decision points throughout the development pipeline.

Read the technical notes:

1. Differentiation of leucine and isoleucine for enhanced sequence variant analysis using electron activated dissociation

2. A peptide mapping workflow with improved MS sensitivity for enhanced PQA characterization

Watch the webinar:

Boost biotherapeutic quality: Innovative approaches to sequence variant analysis | Kristen Nields and Riley Schaeffer, Johnson & Johnson innovative medicine

How NFD improves impurity detection and peak integration in CE SDS workflows

What´s new in SCIEX Now – spring release 2026

The troubleshooting tool LC-MS users have been waiting for

Tags

0 Comments

Submit a Comment Cancel reply

SCIEX Now™ support network

The destination for all your support needs.

Pin It on Pinterest

Share This